Woman dies from brain haemorrhage in Japan days after vaccine, but link uncertain

Send a link to a friend  Share

[March 02, 2021]  TOKYO (Reuters) - A Japanese a woman in her 60s died from a brain haemorrhage three days after receiving a Pfizer coronavirus vaccination, the health ministry said on Tuesday, adding that there may not be a link between the two.

The woman was vaccinated on Friday and is suspected to have suffered a brain haemorrhage three days later, on Monday, it said. It was Japan's first reported death following a vaccination.

"The brain haemorrhage that is suspected as a cause is relatively common among people from their 40s to their 60s, and at this time, based on examples overseas, there does not seem to be a link between brain haemorrhages and the coronavirus vaccine," the ministry quoted Tomohiro Morio, a doctor advising the government, as saying.

"It may be a coincidental case, but there is a need to gather more information and make an assessment in upcoming working groups."

Pfizer officials in Japan were not immediately available for comment. Pfizer said in November the efficacy of its vaccine was consistent across age and ethnic groups, and that there were no major side effects, a sign that the immunisation could be employed broadly around the world.

[to top of second column]

Global health authorities have praised the fast development of safe and effective COVID vaccines, but have warned people with serious underlying health conditions to take medical advice first.

Japan became the last member of the Group of Seven leading industrialised nations to begin its vaccination drive, on Feb. 17.

It has so far received three shipments of vaccine developed by Pfizer and BioNTech.

Japan officially approved Pfizer's vaccine last month, the first such approval in the country as it steps up efforts to tame infections in the run-up to the Summer Olympics.

(Reporting by Ritsuko Ando; Editing by Andrew Heavens and Nick Macfie)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content

 

Back to top